Removal of Adiponectin and Complement Factor D in High dose hemodiafiltration versus High flux hemodialysis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202401461617766

Enrollment

Registered

2024-01-02

Start date

2022-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

Hemodialysis session using FX80 Dialyser

Hemodialysis session using Allmed polypure dialyser

Hemodiafltration session using FX80 Dialyser

Hemodialysis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Twenty patients older than 18 years of age who have been on regular haemodialysis were enrolled. These patients were on high flux filter FX 60 for more than 6 months on a regular schedule of 4-hour sessions thrice weekly. All patients had arteriovenous fistula (AVF). These patients had no residual kidney function.

Exclusion criteria

Exclusion criteria: Patients with active infection, malignancy, dialysis catheters, decompensated heart failure, liver failure and patients who were non-complaint on haemodialysis were excluded.

Design outcomes

Primary

Measure	Time frame
removal of Adiponectin and Complement factor D;Removal of Adiponectin and complement factor D	—

Secondary

Measure	Time frame
urea reduction ratio, potassium removal and bicarbonate increase	—

Countries

Egypt

Contacts

Public Contactlamis khedr

Lecturer of Nephrology

lamis.khedr@med.asu.edu.eg01276209993

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026